Processa Pharmaceuticals' PCS12852 Licensing Agreement with Intact Therapeutics Terminates
PCSA is trading near its 52-week low of $2.05 (11% above the low).
Summary
Processa Pharmaceuticals' binding term sheet with Intact Therapeutics for PCS12852 expired without a definitive license agreement, ending the potential partnership.
Key Events · M&A and Partnerships · PCSA
-
Material Agreement Termination
The binding term sheet dated June 17, 2025, with Intact Therapeutics regarding PCS12852 expired on February 12, 2026.
-
No Definitive License Agreement
A definitive license agreement for PCS12852 was not executed, nor was the related proposed amendment to the License Agreement with Yuhan Corporation.
-
No Further Obligations
Following the expiration, neither Processa Pharmaceuticals nor Intact Therapeutics has any additional obligations under the term sheet.
Analysis · PCSA · Life Sciences
Processa Pharmaceuticals announced the expiration of its binding term sheet with Intact Therapeutics for the drug candidate PCS12852. This means a definitive license agreement was not executed, effectively ending the potential partnership and development path for PCS12852 with Intact Therapeutics. For a micro-cap biotechnology company, the termination of a material agreement related to a drug candidate represents a significant setback, potentially impacting future development, funding, and revenue prospects for that asset.
At the time of this filing, PCSA was trading at $2.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $2.05 to $19.63. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.